Tagged Articles

Invokana and Invokamet 43 articles

British diabetes group issues position statement on DKA risk with certain diabetes drugs

A class of diabetes medications known as SGLT2 inhibitors can increase the risk of a serious condition called diabetic ketoacidosis (DKA), a leading body of diabetes consultants in the United Kingdom said in a recently released position statement. The Association of British Clinical Diabetologists (ABCD) warned physicians to exercise caution when prescribing SGLT2 inhibitors to diabetic patients because the medication elevates their risk of developing DKA, a life threatening condition in which too much acid builds up in the blood. SGLT2 inhibitors, which include the brand name drugs Invokana and Invokamet, are indicated for patients with type 2 diabetes, however they have ... Read More

Diabetics taking Invokana should watch for signs of ketoacidosis

“Diabetic ketoacidosis (DKA) can be deadly,” says Amy Hess-Fishl, an advanced practice dietitian at the University of Chicago Kovler Diabetes Center and member of EndocrineWeb’s advisory board. The condition can occur with diabetic patients and most often those with type 1 diabetes. But patients taking a new class of diabetes drugs known as SGLT2 inhibitors are at an increased risk of developing ketoacidosis. These medications are approved for patients with type 2 diabetes, but the medication is being used off-label on some patients with type 1 diabetes. SGLT2 inhibitors include Invokana and Invokamet. DKA occurs when too much acid builds ... Read More

Diabetics taking SGLT2 should be aware of urinary tract infection symptoms

At least 10 percent of diabetic patients treated with SGLT2 inhibitors will develop a genital fungal infection or lower urinary tract infection, and nearly 20 percent of them will have recurrent infections, researchers reported during a presentation at the American Academy of Physician Assistants. Thus, they urged, it is imperative that doctors treating patients with  these drugs tell them to be aware of the symptoms of these side effects. “You must speak to your patients prescribed sodium glucose co-transporter type 2 (SGLT2) inhibitors about mycotic infection because about 10 percent to 11 percent of your patient population is going to get a ... Read More

Doctors, patients should be aware of the link between diabetes meds and diabetic ketoacidosis

Physician and patient awareness of diabetic ketoacidosis (DKA) risk when using a drug in the SGLT2 Inhibitor class is important to quickly and accurately identify and treat the condition, and is key to improved outcomes for patients in the emergent setting of DKA, advised Deeply Dixit, Pharma, BCPS, in a column in Pharmacy Times. Dixit is a Clinical Assistant Professor at Ernest Mario School of Pharmacy and a Clinical Critical Care Pharmacist in the Medical Intensive Care Unit at Robert Wood Johnson University Hospital. In May 2015, the Food and Drug Administration (FDA) warned that SGLT2 inhibitors, such as the brand-name drugs Invokana, ... Read More

Newer diabetes drugs can affect kidney health

Three months after the Food and Drug Administration (FDA) warned that it was strengthening warnings on the type 2 diabetes drugs canagliflozin (Invokana and Invokamet) and dapagliflozin (Farxiga and Xigduo XR) regarding acute kidney injury, a new study claims the drugs may help protect kidney health. People with type 2 diabetes are already at an increased risk of progressive kidney function loss and kidney disease. Researchers with the University Medical Center Groningen in the Netherlands who conducted the study said that SGLT2 inhibitors may offer therapeutic benefit to diabetics at risk of kidney problems. Three of the study’s authors are ... Read More

Sales of diabetes drug Invokana expected to climb despite new side effects warnings

The global market for diabetes and obesity treatments is expected to rise from $70.8 billion in 2015 to $163.2 billion by 2022, according to business intelligence firm GBI research. One of the drugs named as a key player with a great shot at reaching blockbuster status is Johnson & Johnson and Janssen Pharmaceuticals’ type 2 diabetes drug Invokana. Analysts say that sales of Invokana could reach $3.23 billion by 2022. Sales will be boosted by the obesity epidemic and a growing number of the population being diagnosed with type 2 diabetes. Invokana’s makers are also looking at expanding the drug’s ... Read More

Study shows increased leg and foot amputations with Invokana, Invokamet

A clinical trial assessing heart risk with the newer type 2 diabetes drug canagliflozin, found in the brand-name drugs Invokana and Invokamet, found that patients who used the medication were at an increased risk of leg and foot amputations. The ongoing CANVAS (Canagliflozin Cardiovascluar Assessment Study) was launched four and a half years ago and continues to be evaluated by an independent data monitoring committee. Seven out of every 1,000 patients were treated with 100 mg of canagliflozin daily, five out of every 1,000 were treated with 300 mg daily, and three out of every 1,000 were given a placebo. A one-year ... Read More

Diabetics taking an SGLT2 inhibitor should watch for ketoacidosis signs

Diabetic ketoacidosis, or DKA, is a serious condition that can lead to diabetic coma and even death, warns the American Diabetes Association. Ketoacidosis occurs when the cells don’t get the glucose they need for energy, causing the body to burn fat for energy, which produces ketones. Ketones are chemicals that the body creates when it breaks down fat to use for energy. The body reacts this way when it does not have enough insulin to use glucose, the body’s natural source of energy. When ketones build up in the blood, they make it more acidic. Symptoms of ketoacidosis usually come ... Read More

Johnson & Johnson reaps profits from allegedly dangerous drugs

Johnson & Johnson is swimming in profits. The company announced its 2016 second quarter results that shows sales of $18.5 billion, an increase of 3.9 percent over 2015 second quarter. “We continue to see good momentum through the first half of 2016, delivering solid results in the second quarter, supported by strong underlying growth across our enterprise,” said Alex Gorsky, Chairman and Chief Executive Officer. “We saw notable strength in our Pharmaceuticals business due to the continued success of new products, and also achieved significant clinical milestones, advancing our robust pipeline.” Johnson & Johnson increased its sales guidance for the ... Read More

Invokana beneficial as stand-alone diabetes treatment but side effects mount

Canagliflozin, the active drug ingredient in the type 2 diabetes treatments Invokana and Invokamet, may be especially effective at managing blood sugar levels without being used in combination with the long-used diabetes drug metformin, according to research conducted by the University of Dundee, University of Glasgow, and McMaster University in Canada. Invokana is a single-drug version of canagliflozin whereas Invokamet is a combination of canagliflozin and metformin. The treatments are in a class of diabetes medications called sodium-glucose transporter-2 (SGLT2) inhibitors, which also includes the drugs dapagliflozin (Farxiga and Xigudo XR) and empagliflozin (Jardiance). “We have found that canagliflozin not ... Read More